Natixis Sells 128,455 Shares of Humana Inc. (NYSE:HUM)

Natixis lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 68.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,013 shares of the insurance provider's stock after selling 128,455 shares during the quarter. Natixis' holdings in Humana were worth $14,718,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana during the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA grew its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new position in Humana in the 4th quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. grew its position in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 1.8 %

NYSE:HUM traded up $4.76 during trading hours on Wednesday, reaching $263.68. 1,092,427 shares of the company traded hands, compared to its average volume of 1,757,754. The business's 50-day moving average price is $265.74 and its two-hundred day moving average price is $270.19. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $31.82 billion, a P/E ratio of 26.50, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana's dividend payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Guggenheim assumed coverage on Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. StockNews.com raised shares of Humana from a "hold" rating to a "buy" rating in a research report on Monday, April 7th. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.